cas 851443-04-4, Rosuvastatin ethyl ester | Articles data

Articles about 851443-04-4Total 13 be found

Efficient and highly stereoselective assembly of rosuvastatin
We report an asymmetric synthesis of rosuvastatin starting from an α,β-unsaturated aldehyde precursor containing the rosuvastatin heterocyclic core at its terminus. The α,β-unsaturated carbonyl starting material was used in a highly stereoselective Ti-catalyzed aldol condensation followed by a syn-selective Narasaka–Prasad borane-ketone reduction and hydrolysis step to provide rosuvastatin calcium. This approach provides concise access to stereochemically pure rosuvastatin from simple and readily available starting materials in 3 steps. The overall three-step process provides rosuvastatin calcium in 80% yield, >99:1 syn/anti ratio, and >99% ee.
?terk, Damjan,Zaugg, Werner,Beutler, Ulrich,Loeser, Eric M.,Prasad, Kapa,?asar, Zdenko
p. 1338 - 1341
(2016)
Read Online

Method for synthesizing rosuvastatin ester by using continuous flow tubular reactor
The invention relates to a method for synthesizing rosuvastatin ester by using a continuous flow tubular reactor, which comprises the following steps of (1) mixing a compound 1 with a solvent to obtain a material A, (2) preparing a 0.01-0.05 mol/L sulfuric acid solution to obtain a material B, (3) respectively pumping the material A and the material B into a first tubular reactor for a chemical reaction, wherein the reaction temperature is 35-45 DEG C, and the reaction time is 40-80 s, and after the reaction is finished, adjusting the pH value of the obtained reaction solution to 6.5-7.5, and carrying out liquid separation, vacuum concentration, recrystallization, centrifugation and drying to obtain the target product.The specific synthetic route is as follows. By adopting the method disclosed by the invention, the time required by the whole reaction process is extremely short, the reaction condition is mild, and the situation that by-products are generated due to overlong reaction time or overhigh reaction temperature can be effectively avoided, so that the yield of the target product is high and reaches 97% or above, and the purity of the target product is high and reaches 99% or above.
-
Paragraph 0032-0039; 0043-0045

(2022/01/04)

Statins intermediate and its derivatives
The invention discloses a preparation method for a tatin intermediate and derivatives thereof. The compound adopts a structure shown in a formula I (refer to the specification); the preparation method is that a compound shown in a formula II (refer to the specification) and a nucleophile reagent are subjected to the ring-opening reaction, wherein R is a C1-10 alkoxy group. The preparation method has the advantages that the mild conditions are realized, the reaction operation is simple, the reaction time is short, the product transformation ratio is high and the method is suitable for large-scale production.
-
Paragraph 0024-0025

(2019/04/10)

PROCESS FOR THE MANUFACTURE OF ROSUVASTATIN CALCIUM USING CRYSTALLINE ROSUVASTATIN ETHYL ESTER
The present invention relates to an improved process to prepare Rosuvastatin calcium of Formula (I), with good quality. Further, the present invention also relates to a crystalline polymorphic form of Rosuvastatin ethyl ester.
-
Page/Page column 4-5

(2012/06/18)

PROCESS FOR THE MANUFACTURE OF ROSUVASTATIN CALCIUM USING CRYSTALLINE ROSUVASTATIN ETHYL ESTER
The present invention relates to an improved process to prepare Rosuvastatin calcium of Formula (I), with good quality. Further, the present invention also relates to a crystalline polymorphic form of Rosuvastatin ethyl ester.
-
Page/Page column 16; 17

(2011/04/13)

Highly stereoselective hydrogenations-as key-steps in the total synthesis of statins
Statins are inhibitors of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (HMG-CoA reductase) and became the standard of care for treatment of hypercholesterolemia because of their efficacy, safety, and long-term benefits. They are administered as diaste
Andrushko, Natalia,Andrushko, Vasyl,Tararov, Vitali,Korostylev, Andrei,Koenig, Gerd,Boerner, Armin
scheme or table
p. 534 - 541
(2010/08/20)

PROCESS FOR THE MANUFACTURE OF ROSUVASTATIN CALCIUM WITH HIGH PURITY
The present invention relates to an improved process to prepare Rosuvastatin calcium of Formula (I), with good quality, which comprises a) reducing Rosuvastatin keto ester of Formula (III) with a hydride ion source and dialkylalkoxyborane at law temperatu
-
Page/Page column 9

(2009/10/22)

AN IMPROVED PROCESS FOR PREPARATION OF ROSUVASTATIN CALCIUM
The present invention relates to an improved process for preparing (E)-7-[4-(4-fluorophenyl)- 6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6- enoic acid calcium of Formula (I).
-
Page/Page column 24

(2008/12/08)

PROCESS FOR THE PREPARATION OF ROSUVASTATIN
A process for the manufacture of a compound of formula (V), useful for making rosuvastatin, by a stereoselective aldol reaction is described.
-
Page/Page column 26-27

(2008/12/06)

Synthetic Method and Intermediates of Rosuvastatin Calcium and Preparation Methods of Intermediates
The present invention publicly discloses a synthetic method and intermediates of rosuvastatin calcium and synthetic methods of the intermediates. The synthetic method uses 4-4′-fluorophenyl-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyridine-5-formalde
-
Page/Page column 4

(2008/06/13)

A new approach to the total synthesis of rosuvastatin
A new multi-step synthesis of the lipid-lowering agent rosuvastatin, involving two homogeneously catalyzed reaction steps, is described. The key building block, N-[4-(4-fluorophenyl)-5-formyl-6-isopropylpyrimidin-2-yl]-N- methylmethanesulfonamide (2), was prepared by Pd-catalyzed formylation with CO/H2 (1:1, 50 bar, phosphane ligand/substrate ratio of 1:10). Several alternative pathways for the preparation of 2 were also tested, but were found to be inferior. Rosuvastatin precursor 1 was assembled by Wittig coupling of aldehyde 2 and ylide (R)-3, derived from a Rucatalyzed asymmetric hydrogenation. The second stereogenic center was finally created by stereoselective reduction with Et2BOMe and NaBH4 to afford rosuvastatin ethyl ester. Wiley-VCH Verlag GmbH & Co. KGaA, 2008.
Andrushko, Natalia,Andrushko, Vasyl,Koenig, Gerd,Spannenberg, Anke,Boerner, Armin
scheme or table
p. 847 - 853
(2009/04/11)

PROCESSES FOR THE MANUFACTURE OF ROSUVASTATIN AND INTERMEDIATES
A process for the manufacture of a compound of formula (V), useful for making rosuvastatin, by a stereoselective aldol reaction is described. Novel intermediates and processes to make them are also described.
-
Page/Page column 19

(2010/11/25)

PROCESS FOR THE MANUFACTURE OF THE CALCIUM SALT OF ROSUVATATIN (E)-7-`4- (4-FLUOROPHENYL) -6-ISOPROPYL-2-`METHYL (METHYLSULFONYL) AMINO ! PYRIMIDIN -5-YL ! (3R, 5S) -3, 5-DIHYDROXYHEPT-6-ENOIC ACID AND CRYSTALLINE INTERMEDIATES THEREOF
A process for the manufacture of the calcium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl) amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid, useful as an HMGCoA reductase inhibitor, from a compound of the formula (7) wherein A is an acetal or ketal protecting group and R is alkyl, via isolated crystalline compounds of the formula (8) or of formula (10) is described. Crystalline intermediates of formulae 7, 8 and 10 are also described.
-
Page/Page column 20-21

(2010/02/11)